All Releases
 |
BioCryst to Announce Fourth Quarter and Full Year 2011 Financial Results on February 16, 2012
Feb 6, 2012
|
11.9 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that its fourth
quarter and full year 2011 financial results will be released on
Thursday, February 16, 2012. BioCryst will host a conference call and
webcast at 11:00 a.m. Eastern Time to discus...
|
|
Nancy Hutson Appointed to BioCryst's Board of Directors
Jan 19, 2012
|
10.9 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that Nancy J.
Hutson, Ph.D. was elected to the Company's Board of Directors, effective
Friday, January 20, 2012.
"We are excited to bring Nancy onboard and welcome her to the BioC...
|
|
BioCryst Announces Positive Results from Its Ongoing BCX4208 Phase 2B Study in Patients with Gout
Jan 8, 2012
|
20.1 KB |
| |
Confirmation of favorable BCX4208 safety profile through 24 weeks
Proportion of patients reaching serum uric acid goal sustained
at 24 weeks
BioCryst to host a conference call & webcast Monday, January 9
at 10:00 a.m. ET
RESE...
|
|
BioCryst Pharmaceuticals Presents New BCX4208 Gout Data at the 2011 ACR/ARHP Annual Scientific Meeting
Nov 8, 2011
|
19.2 KB |
| |
BioCryst to host a conference call & webcast today at 7:45 p.m.
Central Time
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) presents new results today from
its Phase 2b randomized, double-blind, dose-response study of BCX4208
in...
|
|
BioCryst Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2011 Financial Results
Nov 2, 2011
|
24.7 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial
results for the third quarter and nine months ended September 30, 2011.
"We are pleased with the recent results of our 12-week Phase 2b gout
study, which showed that addi...
|
|
BioCryst Pharmaceuticals Announces New BCX4208 Gout Data Has Been Accepted as a Late-Breaker Oral Presentation at the ACR/ARHP 2011 Annual Scientific Meeting
Oct 24, 2011
|
15.3 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - News) today announced that results from its Phase 2b randomized, double-blind, dose-response study of BCX4208 in patients with gout who have failed to reach the clinic...
|
|
BioCryst Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 2, 2011
Oct 19, 2011
|
12.4 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third
quarter 2011 financial results will be released on Wednesday, November
2, 2011. BioCryst will host a conference call and webcast at 11:00 a.m.
Eastern Time to discuss the financial ...
|
|
Biocryst Pharmaceuticals Announces Changes to Its Board of Directors
Oct 11, 2011
|
10.6 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the election of George B. Abercrombie to the Company's board of directors, effective Oc...
|
|
BioCryst Announces Positive Top-Line Results from BCX4208 Phase 2B Gout Study in Patients Not Responding to Allopurinol Alone
Oct 5, 2011
|
18.0 KB |
| |
BioCryst to host a conference call & webcast today at 8:30 AM ET
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced positive
top-line results from its Phase 2b randomized, double-blind,
dose-response study of BCX42...
|
|
BioCryst To Present New Peramivir Data at the 51st Annual ICAAC Meeting
Sep 17, 2011
|
16.2 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the
presentation of data related to intravenous
(i.v.) peramivir for the treatment of influenza at the 51st Annual
Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC)
...
|
|
BioCryst to Present at Three Upcoming Investor Conferences
Sep 6, 2011
|
11.7 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives
from BioCryst are scheduled to present a corporate summary and an update
regarding the Company's clinical
programs at the following investor conferences in New York:
...
|
|
CORRECTING and REPLACING BioCryst Provides Corporate Update and Reports Second Quarter 2011 Financial Results
Aug 4, 2011
|
26.3 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
Please replace the release with the following corrected version. Please
note that the following press release contains corrections to the net
operating cash use for both the recent quarter and year to date, which
appeared in BioCryst's earnings release issued earlie...
|
|
BioCryst Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
Jul 26, 2011
|
12.3 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals (NASDAQ:BCRX) today announced that its second
quarter 2011 financial results will be released on Thursday, August 4,
2011. BioCryst will host a conference call and webcast at 11:00 a.m.
Eastern Time to discuss the financial results ...
|
|
Kenneth Lee Appointed to BioCryst Pharmaceuticals' Board of Directors
Jun 27, 2011
|
11.1 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Kenneth B.
Lee, Jr., was elected to the Company's board of directors, effective
today. He will also serve on the audit committee of the Board.
"Ken Lee brings to the BioCryst ...
|
|
BioCryst to Present at Two Upcoming Investor Conferences
May 31, 2011
|
10.7 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives
from BioCryst are scheduled to present and provide a corporate summary
and update regarding the Company's clinical programs at the following
investor conferences:
...
|
|
BioCryst Presents New Analyses of BCX4208 Phase 2 Studies in Patients with Gout at the Annual European Congress of Rheumatology
May 26, 2011
|
17.2 KB |
| |
Ongoing BCX4208 Phase 2b add-on study exceeds enrollment target
BioCryst will host a conference call & webcast today at 6 p.m.
GMT (1 p.m. ET)
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCR...
|
|
BioCryst Pharmaceuticals Announces Appointment of Thomas Staab as Its Next Chief Financial Officer
May 25, 2011
|
12.2 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment
of Mr. Thomas R. Staab, II as BioCryst's new Chief Financial Officer,
effective July 1, 2011, and that Mr. Stuart R. Grant, BioCryst's current
CFO, has agreed to extend his employm...
|
|
BioCryst Provides Corporate Update and Reports First Quarter 2011 Financial Results
May 4, 2011
|
20.7 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial
results for the first quarter ended March 31, 2011.
Recent Highlights
In February, BioCryst announced that it was awarded a $55 million
cont...
|
|
BioCryst Pharmaceuticals Announces Changes to Its Board of Directors
May 3, 2011
|
12.2 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Peder
Jensen, M.D., was elected to the Company's Board of Directors, effective
today. The Company also announced today that Beth
C. Seidenberg, M.D., has tendered her resignation from the Boa...
|
|
BioCryst to Present at Bank of America Merrill Lynch Healthcare Conference
May 3, 2011
|
10.5 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that Jon
Stonehouse, President and Chief Executive Officer of BioCryst, plans
to provide a corporate summary and update regarding the Company's
clinical programs at the Bank of America Merrill Ly...
|
|
|
